Brown Miller Wealth Management LLC Purchases 3,178 Shares of Novo Nordisk A/S (NYSE:NVO)

Brown Miller Wealth Management LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 38.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,394 shares of the company's stock after buying an additional 3,178 shares during the quarter. Brown Miller Wealth Management LLC's holdings in Novo Nordisk A/S were worth $791,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in NVO. Center for Financial Planning Inc. increased its stake in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares during the period. Strategic Investment Solutions Inc. IL grew its holdings in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $33,000. Finally, CX Institutional bought a new position in Novo Nordisk A/S in the first quarter worth $36,000. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

NVO has been the subject of a number of recent research reports. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, BMO Capital Markets restated a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded down $2.81 during mid-day trading on Monday, hitting $77.02. 8,140,859 shares of the stock were exchanged, compared to its average volume of 7,046,871. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The stock's fifty day simple moving average is $67.30 and its two-hundred day simple moving average is $79.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market cap of $345.62 billion, a P/E ratio of 23.41, a PEG ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.